The role of serotonin in schizophrenia

Altar, 1988, Dopamine neurochemical profile of atypical antipsychotics resembles that of D-1 antagonists, Naunyn-Schmiedeberg's Arch. Pharmacol., 338, 162, 10.1007/BF00174864 Anderson, 1993 Anderson, 1986, Evidence for different states of the dopamine D-1 receptor: Clozapine and fluperlapine may preferentially label and adenylate cyclase-coupled state of the D-1 receptor, J. Neurochem., 47, 1822, 10.1111/j.1471-4159.1986.tb13094.x Arora, 1982, Serotonin uptake by blood platelets of schizophrenic patients, Psychiatry Res., 6, 327, 10.1016/0165-1781(82)90022-1 Arora, 1983, Effects of chlorpromazine on serotonin uptake in blood platelets, Psychiatry Res., 9, 23, 10.1016/0165-1781(83)90085-9 Arora, 1993, Serotonin2 receptor binding in blood paltelets of schizophrenic patients, Psychiatry Res., 47, 111, 10.1016/0165-1781(93)90041-E Ashcroft, 1986, 5-Hydroxyindole compounds in the cerebrospinal fluid of patients with psychiatric or neurologic disease, Lancet, II, 1049 Banki, 1984, Cerebrospinal fluid amine metabolites and neuroendocrine charges in psychoses and suicide', 153 Beasely, C. (1994) Personal communication. Bersani, 1986, Neuroleptic induced extrapyramidal side effects: Clinical perspectives with ritanserin (R35667), a new selective 5HT2a receptor blocking agents, Curr. Ther. Res., 60, 492 Bjök, 1992, Amperizode in the treatment of schizophrenic patients, 47 Blandina, 1988, Activation of a 5HT3 receptor releases dopamine from rate striatal slices, Eur. J. Pharmacol., 155, 249, 10.1016/0014-2999(88)90528-6 Bleich, 1991, A serotonergic theory of schizophrenia, 183 Borison, 1992, Clinical overview of risperidone, 233 Borison, 1992, Risperidone: Clinical safety and efficacy in schizophrenia, Psychopharmacol. Bull., 28, 213 Bowers, 1974, Central dopamine turnover in schizophrenic syndromes, Arch. Gen. Psychiatry, 31, 50, 10.1001/archpsyc.1974.01760130034005 Bowers, 1969, Cerebrospinal fluid, 5-hydroxyindoleacetic acid and homovanillic acid in psychiatric patients', Int. J. Neuropharmacol., 8, 255, 10.1016/0028-3908(69)90046-X Braunig, 1989, Blood serotonin level in suicidal schizophrenia patients, Acta Psychiatr. Scand., 79, 186, 10.1111/j.1600-0447.1989.tb08586.x Brier, 1993, Clozapine attenuates metachlorophenyl piperazine (mCPP)-induced plasma cortisol increases in schizophrenia, Biol. Psychiatry, 34, 492, 10.1016/0006-3223(93)90241-5 Ceulemans, 1985, Effect of serotonin antagonism in schizophrenia: A pilot study with setoperone, Psychopharmacology, 85, 329, 10.1007/BF00428197 Ceulemans, 1985, Therapeutic efficacy of serotonin and dopamine antagonism on positive and negative symptoms of chronic schizophrenic patients, 279 Chen, 1989, Anatomically selective action on mesolimbic serotonergic mechanisms by clozapine: In vivo brain microdialysis studies Chouinard, 1993, Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients, J. Clin. Psychopharmacol., 13, 25, 10.1097/00004714-199302000-00004 Claghorn, 1987, The risks and benefits of clozapine versus chlorpromazine, J. Clin. Psychopharmacol., 7, 377, 10.1097/00004714-198712000-00002 Cooper, 1992, 5-hydroxyindoleacetic acid in cerebrospinal fluid and prediction of suicidal behavior in schizophrenia, Lancet, 340, 940, 10.1016/0140-6736(92)92819-2 Costall, 1987, Effects of the 5HT3 receptor agonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain, Br. J. Pharmacol., 92, 881, 10.1111/j.1476-5381.1987.tb11394.x Costall, 1988, Zacopride: anxiolytic profile in rodent and primate models of anxiety, J. Pharmacol., 40, 302, 10.1111/j.2042-7158.1988.tb05254.x Costall, 1989, Neuroanatomical sites of action of 5HT3 receptor antagonists for alteration of aversive behavior in the mouse, Br. J. Pharmacol., 96, 325, 10.1111/j.1476-5381.1989.tb11821.x Costall, 1993, The pharmacology of 5HT4 receptors, Int. Clin. Psychopharmacol., 8, 11, 10.1097/00004850-199311002-00002 Cowen, 1985, Responses of prolactin and growth hormone to l-tryptophan infusion: Effects in normal subjects and schizophrenic patients receiving neuroleptics, Psychopharmacology, 86, 164, 10.1007/BF00431703 Creese, 1986, Biochemical characteristics of D1-dopamine receptors: Relationship to behavior and schizophrenia, Clin. Neuropharmacol., 9, 14 Crow, 1979, Monoamine mechanisms in chronic schizophrenia: Postmortem neurochemical findings, Br. J. Psychiatry, 134, 249, 10.1192/bjp.134.3.249 Csernansky, 1990, 5HIAA in cerebrospinal fluid and deficit schizophrenic characteristics, Br. J. Psychiatry, 156, 501, 10.1192/bjp.156.4.501 DeLisi, 1981, Increased whole blood seotonin concentrations in chronic schizophrenic patients, Arch. Gen. Psychiatry, 38, 647, 10.1001/archpsyc.1981.01780310047004 Eriksson, 1990, Amperozide, a putative antipsychotic drug: uptake inhibition and release of dopamine in vitro in the rat brain, Life Sci., 47, 2111, 10.1016/0024-3205(90)90310-N Ellenbroek, 1989, Are antagonists of dopamine D1 receptors drugs that attenuate both positive and negative symptoms of schizophrenia?, Neuropsychopharmacology, 2, 191, 10.1016/0893-133X(89)90022-5 Farely, 1980, Brain monoamine changes in chronic paranoid schizophrenia and their possible relation to increased dopamine receptor sensitivity, 427 Feldstein, 1959, Blood and urinary serotonin and 5-hydroxyindoleacetic acid levels in schizophrenic patients and normal subjects, J. Nerv. Dis., 129, 62, 10.1097/00005053-195907000-00007 Freedman, 1981, Blood tryptophan metabolism in chronic schizophrenics, Arch. Gen. Psychiatry, 38, 655, 10.1001/archpsyc.1981.01780310055005 Gardner, 1988, Anatomically selective action of atypical neuroleptics on the mesocorticolimbic dopamine system, Ann. NY Acad. Sci., 585, 502, 10.1111/j.1749-6632.1988.tb42140.x Garelis, 1975, Elevated blood serotonin concentrations in unmedicated chronic schizophrenic patients: A preliminary study, Am. J. Psychiatry, 132, 184, 10.1176/ajp.132.2.184 Gataz, 1982, CSF monoamine metabolism in schizophrenic patients, Acta Psychiatr. Scand., 66, 350, 10.1111/j.1600-0447.1982.tb06717.x Geiss, 1992, The effects of a novel 5HT3 antagonist, ondansetron, in schizophrenia. Results from uncontrolled trials, 22 Gelders, 1985, Ritanserin, a selective serotonin agonist, in chronic schizophrenia, 338 Gelders, 1985, The influence of selective serotonin antagonism on conventional neuroleptic therapy, 417 Gentsch, 1985, [3H]Imipramine binding sites in platelets of hospitalized psychiatric patients, Psychiatry Res., 14, 177, 10.1016/0165-1781(85)90012-5 Gonzalez-Heydrich, 1990, Serotonin receptor and reuptake sites: Pharmacologic significance, J. Clin. Psychiatry, 51, 5 Heinrich, 1991, Experimental comparison of the efficacy and compatibility of risperidone and clozapine in acute schizophrenia, 37 Herve, 1987, Serotonin axis terminals in the ventral segmental area of the rat: Fine structure and synaptic input to dopaminergic neurons, Brain Res., 435, 71, 10.1016/0006-8993(87)91588-5 Hoshino, 1985, Endocrinological function in schizophrenic patients under haloperidol treatment: Plasma, PRL, HGH and 5HT levels after L-5HTP loading, Folia Psychiatr. Neurol. Japan., 39, 123 Hoyer, 1988, Functional correlates of serotonin 5HT, recognition sites, J. Receptor Res., 8, 59, 10.3109/10799898809048978 Hoyer, 1986, Serotonin receptors in the human brain, Brain Res., 376, 85, 10.1016/0006-8993(86)90902-9 Humphrey, 1993, A proposed new nomenclature for 5HT receptors, Trends Pharmacolog. Sci., 14, 233, 10.1016/0165-6147(93)90016-D Ichikawa, 1991, Differential effects of repeated treatment with haloperidol and clozapine on dopamine release and metabolism in the striatum and the nucleus accumbens, J. Pharmacol. Exp. Ther., 256, 348 Ichikawa, 1992, Amperozide, a novel antipsychotic drug, inhibits the ability of D-amphetamine to increase dopamine release in vivo in rat structure and nucleus accumbens, J. Neurochem., 58, 2285, 10.1111/j.1471-4159.1992.tb10975.x Igbal, 1990 Igbal, 1991, The MCPP challenge test in schizophrenia: Hormonal and behavioral responses, Biol. Psychiatry, 30, 770, 10.1016/0006-3223(91)90233-C Iqbal, 1991, The role of serotonin in schizophrenia: New findings, Schizophr. Res., 5, 181, 10.1016/0920-9964(91)90046-T Iqbal, 1993, Serotonin and schizophrenia, Psychiatr. Ann., 23, 186, 10.3928/0048-5713-19930401-07 Jackman, 1983, Platelet serotonin levels in schizophrenia: Relationship to race and psychopathology, Biol. Psychiatry, 18, 887 Jackson, 1989, Dopamine D-2 receptor antagonist-induced behavioural depression: Critical dependence upon postsynaptic dopamine D-1 function, Arch. Pharmacol., 340, 355, 10.1007/BF00167035 Janssen, 1988, Pharmacology of risperidone (R 64 766), a new antipsychotic with Serotonin-S2 and Dopamine-D2 antagonistic properties, J. Pharmacol. Exp. Ther., 244, 685 Jones, 1988, The potential anxiolytic activity of GR38032F, a 5HT3 receptor antagonist, Br. J. Pharmacol., 93, 985, 10.1111/j.1476-5381.1988.tb11489.x Joseph, 1977, Platelet serotonin concentration and monoamine oxidase activity in unmedicated chronic schizophrenics and schizophrenic patients, Psychol. Med., 7, 159, 10.1017/S0033291700023230 Joseph, 1979, Brain tryptophan metabolism in schizophrenia: A postmortem study of metabolites on the serotonin and kynurenine pathways in schizophrenic and control subjects, Psychopharmacology, 62, 279, 10.1007/BF00431959 Kahn, 1988, Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder, Psychopharmacology, 96, 360, 10.1007/BF00216062 Kahn, 1992, Serotonin function and treatment response to clozapine in schizophrenic patients, Am. J. Psychiatry, 150, 1337 Kahn, 1992, Serotonin function in schizophrenia: Effects of metachlorophenylpiperazine in schizophrenic patients and healthy subjects, Psychiatry Res., 43, 1, 10.1016/0165-1781(92)90136-Q Kahn, 1991, M-chlorophenylpiperazine as a probe of serotonin function, Biol. Psychiatry, 30, 1139, 10.1016/0006-3223(91)90184-N Kane, 1988, Clozapine for the treatmentresistant schizophrenic: A double-blind comparison and chlorpromazine, Arch. Gen. Psychiatry, 45, 789, 10.1001/archpsyc.1988.01800330013001 Kanof, 1987, Platelet [3H]imipramine binding in psychiatric disorders, Biol. Psychiatry, 22, 278, 10.1016/0006-3223(87)90146-6 Kaplan, 1982, Altered platelet serotonin uptake kinetics in schizophrenia and depression, Life Sci., 31, 583, 10.1016/0024-3205(82)90488-X Kay, 1987, The Positive and Negative Syndrome Scale (PANSS) for schizophrenia: Development and standardization, Schizophr. Bull., 13, 261, 10.1093/schbul/13.2.261 King, 1985, Serotonin and schizophrenia: Correlations between serotonergic activity and schizophrenic motor behavior, Psychiatry Res., 14, 235, 10.1016/0165-1781(85)90018-6 Kolakowska, 1987, Platelet serotonin concentration in schizophrenic patients, Am. J. Psychiatry, 144, 232, 10.1176/ajp.144.2.232 Korpi, 1986, Serotonin and 5hydroxyindoleacetic acid in the brains of suicide victims. Comparison in chronic schizophrenic patients with suicide as cause of death, Arch. Gen. Psychiatry, 43, 594, 10.1001/archpsyc.1986.01800060088011 Krystal, 1992 Krystal, 1992 Krystal, 1993, m-Chlorophenyl piperazine effects in neuroleptic-free schizophrenic patients: Evidence implicating serotonergic systems in the positive symptoms of schizophrenia, Arch. Gen. Psychiatry, 50, 624, 10.1001/archpsyc.1993.01820200034004 Lemus, 1990, CSF 5-hydroxyindoleacetic acid levels and suicide attempts in schizophrenia, Biol. Psychiatry, 27, 926, 10.1016/0006-3223(90)90475-H Lerer, 1988, Neuroendocrine responses in chronic schizophrenia. Evidence for serotonergic dysfunction, Schizophr. Res., 1, 405, 10.1016/0920-9964(88)90022-9 Lesch, 1990, Subsensitivity of the 5-hydroxytryptamine 1A(5HT1A) receptor-mediated hypothermic response to ipsairone unipolar depression, Life Sci., 46, 1271, 10.1016/0024-3205(90)90359-Y Lesch, 1989, Endocrine responses to 5HT1a receptor activation by ipsapirone in humans, Biol. Psychiatry, 36, 203, 10.1016/0006-3223(89)90024-3 Lieberman, 1991, The effect of clozapine on tardive dyskinesia, Br. J. Psychiatry, 158, 503, 10.1192/bjp.158.4.503 Lin, 1992, The preliminary study of monoamine oxidase activity in platelets in patients with schizophrenia and affective disorder, Chung-Hua Shen Ching Ching Shen Ko Tsa Chih, 25, 325 Lindenmayer, 1993, Recent advances in pharmacotherapy of schizophrenia, Psychiatr. Ann., 23, 199, 10.3928/0048-5713-19930401-09 Lindenmayer, 1990, Fluoxetine in chronic schizophrenia, J. Clin. Psychopharmacol., 19, 76, 10.1097/00004714-199002000-00031 Lingjaerde, 1983, Serotonin uptake and efflux in blood platelets from untreated and neuroleptic-treated schizophrenics, Biol. Psychiatry, 18, 1345 Losonczy, 1986, Correlates of lateral ventricular size in chronic schizophrenics, I: Behavioral and treatment response measures, Am. J. Psychiatry, 143, 976, 10.1176/ajp.143.8.976 Marcolin, 1992, Platelet monoamine oxidase in schizophrenia: a meta-analysis, Schizophr. Res., 7, 249, 10.1016/0920-9964(92)90019-2 Matsubara, 1989, Effect of typical and atypical antipsychotic drugs on 5HT2a receptor density in rat cerebral cortex, Life Sci., 45, 1397, 10.1016/0024-3205(89)90027-1 Meert, 1989, Risperidone (R 64 766), a potent and complete LSD antagonist in drug discrimination by rats, Psychopharmacology, 97, 206, 10.1007/BF00442251 Meibach, 1993, A fixed-dose, parallel group study of risperidone vs. haloperidol vs. placebo, Schizophr. Res., 9, 245, 10.1016/0920-9964(93)90550-3 Meltzer, 1989, Clozapine: Clinical advantages and biological mechanisms, 302 Meltzer, 1990, Clozapine: Mechanism of action in relation to its clinical advantages, 237 Meltzer, 1991, Studies of ondansetron in schizophrenia, Biol. Psychiatry, 2, 891 Meltzer, 1992, The mechanism of action of clozapine in relation to its clinical advantages, 1 Meltzer, 1993, Serotonin-dopamine interactors and atypical antipsychotic drugs, Psychiatr. Ann., 23, 193, 10.3928/0048-5713-19930401-08 Meltzer, 1979, Effect of clozapine on human serum prolactin levels, Am. J. Psychiatry, 136, 1550, 10.1176/ajp.136.12.1550 Meltzer, 1989, Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pki values, J. Pharmacol. Exp. Ther., 251, 238 Modai, 1979, Serotonin uptake by blood platelets of acute schizophrenic patients, Psychopharmacology, 64, 193, 10.1007/BF00496061 Muck-Seler, 1988, Time course of schizophrenia and platelet 5HT level, Biol. Psychiatry, 23, 243, 10.1016/0006-3223(88)90035-2 Muck-Seler, 1991, Platelet serotonin in subtypes of schizophrenia and unipolar depression, Psychiatry Res., 38, 105, 10.1016/0165-1781(91)90036-O Muller-Spahn, 1992, Risperidone in the treatment of chronic schizophrenic patients: An international double-blind parallel group study versus haloperidol, The International Risperidone Research Group. Clin. Neuropharmacol., 90A, 10.1097/00002826-199201001-00048 Newcomer, 1992, Zacopride in schizophrenia: A single-blind serotonin type 3 antagonist trial, Arch. Gen. Psychiatry, 69, 751 Ninan, 1984, CSF 5-hydroxyindoleacetic acid levels in suicidal schizophrenic patients, Am. J. Psychiatry, 141, 56 Nissbrandt, 1992, The influence of serotonergic drugs on dopamine neurotransmission in rat substantia nigra, striatum, and limbic system in vivo, NaunynSchmiedeberg's Arch. Pharmacol., 346, 12, 10.1007/BF00167564 Nyback, 1983, Cerebroventricular size and cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy volunteers, Psychiatry Res., 9, 301, 10.1016/0165-1781(83)90003-3 Nyberg, 1993, 5HT2a and D2 dopamine receptor occupancy in the living human brain, Psychopharmacology, 110, 265, 10.1007/BF02251280 Owen, 1993, Effects of clozapine and fluphenazine treatment on resonses to m-Chlorophenyl Piperazine (mCPP) infusions in schizophrenia, Arch. Gen. Psychiatry, 50, 636, 10.1001/archpsyc.1993.01820200046005 Peroutka, 1991, Central 5HT receptors: Functional correlates and clinical relevance, 8 Persson, 1969, Acid metabolites from monoamines n-cerebrospinal fluid of schizophrenics, Br. J. Psychiatry, 115, 95, 10.1192/bjp.115.518.95 Pickar, 1992, Clinical and biologic response to clozapine in patients with schizophrenia: Crossover and fluphenazine, Arch. Gen. Psychiatry, 49, 345, 10.1001/archpsyc.1992.01820050009001 Post, 1975, Cerebrospinal fluid amine metabolites in acute schizophrenia, Arch. Gen. Psychiatry, 32, 1063, 10.1001/archpsyc.1975.01760260127011 Potkin, 1983, Low CSF 5-hydroxyindoleacetic acid in schizophrenic patients with enlarged cerebral ventricles, Am. J. Psychiatry, 140, 21, 10.1176/ajp.140.1.21 Rimon, 1971, The content of 5HIAA and HVA in the CSF of patients with acute schizophrenia, J. Psychosom. Res., 15, 375 Risch, 1993 Rotman, 1979, Active uptake of serotonin by blood platelets of schizophrenic patients, FEBS Lett., 101, 134, 10.1016/0014-5793(79)81311-3 Rotman, 1982, Correlation between serotonin uptake and imipramine binding in schizophrenic patients, Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 6, 57, 10.1016/S0364-7722(82)80108-2 Rotman, 1982, The active uptake of serotonin by platelets of schizophrenic patients and their families: Possibility of a genetic marker, Psychopharmacology, 77, 171, 10.1007/BF00431943 Roy, 1985, CSF metabolites in chronic schizophrenic patients who attempt suicide, Psychol. Med., 15, 335, 10.1017/S0033291700023618 Sedvall, 1980, Aberrant monoamine metabolite levels in CSF and family history of schizophrenia, Arch. Gen. Psychiatry, 37, 1113, 10.1001/archpsyc.1980.01780230031004 Seibyl, 1989 Small, 1993, Risperidone versus clozapine in resistant schizophrenia Sorensen, 1989, Effect of acute and chronic MDL 73, 147EF, a 5HT3 receptor antagonist on A9 and A10 dopamine neurons, Eur. J. Pharmacol., 163, 115, 10.1016/0014-2999(89)90402-0 Stahl, 1983, Hyperserotonemia and platelet serotonin uptake and release in schizophrenia and affective disorders, Am. J. Psychiatry, 140, 26, 10.1176/ajp.140.1.26 Syzmanski, 1993, Selective review of recent advances in the management of tardive dyskinesia, Psychiatr. Ann., 23, 209, 10.3928/0048-5713-19930401-10 Titeler, 1988, Radioligand binding evidence implicates the brain 5HT2a receptor as a site of action for LSD and phenylisopropylamine hallucinogens, Psychopharmacology, 94, 213, 10.1007/BF00176847 Todrick, 1960, Blood platelet 5HT levels in psychiatric patients, J. Ment. Sci., 106, 884, 10.1192/bjp.106.444.884 Tuomisto, 1985, Neurotransmitter regulation of anterior pituitary hormones, Pharmacol. Rev., 37, 249 Van Peer, 1992, Risperidone dose-proportionality in psychotic patients using a population pharmacokinetic analysis, Pharmaceut. Weekbl. Sci. Ed., 14, D10 van Praag, 1983, CSF 5-HIAA and suicide in non-depressed schizophrenics, Lancet, ii, 977, 10.1016/S0140-6736(83)90501-9 van Praag, 1992, Serotonergic mechanisms in the pathogenesis of schizophrenia, 187 Vanden Bussche, 1988, Pharmacokinetic profile and neuroendocrine effects of the new antipsychotic risperidone, Psychopharmacology, 96, 334 Waeber, 1988, Visualization of a novel serotonin recognition site (5HT1d) in the human brain by autoradiography, Neurosci. Lett., 88, 11, 10.1016/0304-3940(88)90307-2 Weizman, 1987, Platelet [3H]imipramine binding in autism and schizophrenia, Psychopharmacology, 91, 101, 10.1007/BF00690935 Williams, 1983, The involvement of 5-hydroxytryptamine in the release of dendritic dopamine from slices of rat substantia nigra, J. Pharm. Pharmacol., 35, 734, 10.1111/j.2042-7158.1983.tb02880.x Winblad, 1979, Monoamines and monoamine metabolites in brains from demented schizophrenics, Acta Psychiatr. Scand., 60, 17, 10.1111/j.1600-0447.1979.tb00261.x Wood, 1983, Lack of association between [3H]imipramine binding sites and uptake of serotonin in control, depressed and schizophrenic patients, Neuropharmacology, 22, 1211, 10.1016/0028-3908(83)90083-7 Zohar, 1987, Serotonergic responsivity in obsessivecompulsive disorder, Arch. Gen. Psychiatry, 44, 946, 10.1001/archpsyc.1987.01800230026006